Teleflex Completes Patient Enrollment In BIOMAG-LL Clinical Study, Evaluating Freesolve RMS In 35 mm And 40 mm Lengths For Treatment Of De Novo Coronary Lesions Up To 38 mm
102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds in long coronary lesionsTeleflex Incorporated (NYSE:TFX), a leading
Teleflex finished testing a new heart device on 102 patients in Europe. Watch for results to see if this product works well and is safe.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.